Opendata, web and dolomites

uCARE SIGNED

Understanding Circumventing Antibiotic REsistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 uCARE project word cloud

Explore the words cloud of the uCARE project. It provides you a very rough idea of what is the project "uCARE" about.

systematically    uncover    polypharmacy    counteract    possibly    lived    yield    equally    again    antibacterial    combinations    bacterial    driver    basis    unnoticed    human    drugs    cross    identification    elucidate    map    health    hitherto    ways    once    proteome    heels    achilles    treatable    antimicrobial    antidotes    drug    imperative    public    experimental    indicate    data    seek    bacteria    revisiting    mechanisms    reverse    implies    severity    issue    full    policies    proof    line    profiling    repertoire    chemical    candidates    broad    prevent    diseases    living    preliminary    evolution    cellular    deadly    reverting    delay    throughput    genetic    resistance    tens    thermal    undermining    antibiotics    fundamental    genetics    mode    utmost    drivers    biological    standards    principles    action    250    antibiotic    revert    direct    expose    therapies    medication    networks    it    spread    microbes    gut    longer    paths    underlying   

Project "uCARE" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN MOLECULAR BIOLOGY LABORATORY 

Organization address
address: Meyerhofstrasse 1
city: HEIDELBERG
postcode: 69117
website: http://www.embl.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙986˙004 €
 EC max contribution 1˙986˙004 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) coordinator 1˙986˙004.00

Map

 Project objective

The evolution and spread of antibiotic resistance has become a public health concern of the utmost severity, making once treatable diseases deadly again and undermining our living standards. New therapies are imperative, but equally important are the understanding of the full repertoire of drivers of antibiotic resistance and the identification of ways to counteract them. We have recently established that ~250 non-antibiotic drugs have direct, strong and often broad antibacterial effects on human gut microbes. Moreover, preliminary data indicate that bacteria use similar general resistance mechanisms against both drugs with human targets and antibiotics. This implies that polypharmacy may be a hitherto unnoticed driver of antibiotic resistance. We will use chemical genetics and experimental evolution to systematically map the cross-resistance between human-targeted drugs and antibiotics, and elucidate underlying resistance mechanisms. Using these data, we will next seek to identify antidotes for the antimicrobial side-effects of non-antibiotic drugs, and exploit human-targeted drugs for reverting existing antibiotic resistance. At the genetic level, we will use high-throughput reverse genetics to expose the Achilles heels of bacterial cellular networks for resistance development. Finally, we will uncover the antimicrobial mode of action of tens of human-targeted drugs using thermal proteome profiling and chemical genetics. Together with the genetic information, this line of research will yield design principles and possibly new drug candidates for longer-lived, resistance-proof drug combinations. Overall, this project aims at improving our fundamental biological understanding of antibiotic resistance and the paths to prevent, delay or revert it. It can also set the basis for revisiting current medication policies. The derived principles are likely to be relevant to other diseases and therapies, in which resistance development is an issue.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

CARBOFLOW (2020)

Streamlined carbon dioxide conversion in ionic liquids – a platform strategy for modern carbonylation chemistry

Read More  

NEUROPRECISE (2019)

Precision medicine in traumatic brain injury using individual neurosteroid response

Read More